Search results
Results from the WOW.Com Content Network
The CRISPR Journal is a peer-reviewed scientific journal published every three months by Mary Ann Liebert. It covers research on all aspects of CRISPR research, including its uses in synthetic biology and genome editing .
Journal Citation Reports (JCR) is an annual publication by Clarivate. [1] It has been integrated with the Web of Science and is accessed from the Web of Science Core Collection. It provides information about academic journals in the natural and social sciences, including impact factors. JCR was originally published as a part of the Science ...
The impact factor relates to a specific time period; it is possible to calculate it for any desired period. For example, the JCR also includes a five-year impact factor, which is calculated by dividing the number of citations to the journal in a given year by the number of articles published in that journal in the previous five years. [14] [15]
Cell Reports is a peer-reviewed scientific journal publishing research papers across a broad range of disciplines within the life sciences. [1] The journal was established in 2012 and is the first open access journal published by Cell Press , an imprint of Elsevier .
PubMed Central (PMC) is a free digital repository that archives open access full-text scholarly articles that have been published in biomedical and life sciences journals. As one of the major research databases developed by the National Center for Biotechnology Information (NCBI), PubMed Central is more than a document repository.
It was founded in 2000 and launched its first journal, PLOS Biology, in October 2003. As of 2024, PLOS publishes 14 academic journals, [2] including 7 journals indexed within the Science Citation Index Expanded, and consequently 7 journals ranked with an impact factor. PLOS journals are included in the Directory of Open Access Journals (DOAJ).
From the early outbreak of the COVID-19 pandemic, rumors and speculation arose about the possible lab origins of SARS-CoV-2, the causative agent of the COVID-19 disease.. Different versions of the lab origin hypothesis present different scenarios in which a bat-borne progenitor of SARS-CoV-2 may have spilled over to humans, including a laboratory-acquired infection of a natural or engineered vir
The world's first COVID-19 drug designed by generative AI is approved for human use, with clinical trials expected to begin in China. The new drug, ISM3312, is developed by Insilico Medicine. [389] A new AI algorithm developed by Baidu is shown to boost the antibody response of COVID-19 mRNA vaccines by 128 times. [390]